<DOC>
	<DOCNO>NCT00550446</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety , 6 month , 5 dos CP-690,550 treatment adult active rheumatoid arthritis . Five seven subject receive CP-690,550 . One seven receive adalimumab ( Humira® ) one seven receive inactive substance ( placebo . )</brief_summary>
	<brief_title>A Phase 2 Study For Patients With A Physician 's Diagnosis Of Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects must active rheumatoid arthritis Subjects must fail least 1 disease modify antirheumatic drug ( DMARD ) Subjects must currently take DMARD antimalarial Subjects discontinue previous TNF inhibitor therapy either lack benefit safety . Subjects previously receive adalimumab ( Humira® ) therapy reason . Subjects evidence blood disorder , chronic infection untreated tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Janus Kinase 3 Clinical Trial</keyword>
</DOC>